14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today AFMD ranks #16087 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Affimed N.V. Stock Forecast NASDAQ:AFMD

$4.44 (0.68%)

Volume: 990k

Closed: Jan 14, 2022

Hollow Logo Score: -6.103

Affimed N.V. Stock Forecast

$4.44 (0.68%)

Volume: 990k

Closed: Jan 14, 2022

Score Hollow Logo -6.103

Affimed N.V. Company Profile


Heidelberg 69120

49 6221 65307 0


Industry: Biotechnology

Sector: Healthcare

Affimed N.V.


Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The company’s product candidates also include AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Its AFM21 product also binds CD3, directing T-cells to destroy tumor cells that carry EGFRvIII. Affimed N.V. has license agreements with Amphivena Therapeutics, Inc. and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and clinical research collaboration with Merck & Co Inc. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE